Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan in intermediate-risk non-muscle invasive bladder cancer
2024-514983-23-01Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 6
01
Overview
Phase 2 trial of sacituzumab tirumotecan in non-muscle-invasive bladder cancer (NMIBC), sponsored by Merck & Co. Started Dec 2024; status: completed.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2024-514983-23-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514983-23-01.